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CONSPECTUS
Short DNA or RNA oligonucleotides have tremendous potential as therapeutic agents. Because of
their ability to engage in Watson-Crick base pairing they can interact with messenger mRNA or
pre-mRNA targets with high selectivity and thus offer the possibility of precise manipulation of
gene expression. This possibility has engendered extensive efforts to develop oligonucleotides as
drugs, with many candidates already in clinical trials. However, a major impediment to the
maturation of oligonucleotide-based therapeutics is the fact that these relatively large and usually
highly charged molecules have great difficulty crossing cellular membranes and thus in
penetrating to their sites of action in the cytosol or nucleus. In this Account we first summarize
some basic aspects of the biology of antisense and siRNA oligonucleotides and then discuss
chemical conjugation as an approach to improving the intracellular delivery and therapeutic
potential of these agents. Our emphasis will be on the pharmacological ramifications of
oligonucleotide conjugates rather than the details of conjugation chemistry. One important
approach has been conjugation with ligands designed to bind to particular receptors and thus
provide specificity to the interaction of cells with oligonucleotides. Another approach has been to
couple antisense or siRNA with agents such as cell penetrating peptides that are designed to
provoke escape of the conjugate from intracellular vesicular compartments. Both of these
approaches have enjoyed some success. However, there remains much to be learned before
oligonucleotide conjugates can find an important place in human therapeutics.
1. Basic Aspects of Oligonucleotide Biology
Classic Antisense Oligonucleotides
Relatively short (≥16 bases) oligonucleotides that are readily prepared by convenient solid
phase synthesis can provide highly selective recognition among the multiple RNAs derived
from the human genome. Upon introduction into cells, DNA antisense oligonucleotides can
enter the nucleus and engage in specific base pairing with complementary sequences in pre-
mRNA. The formation of a DNA/RNA hybrid results in the recruitment of the enzyme
RNaseH that can cleave the RNA, which then triggers further degradation of the cleaved
fragments by other enzymatic processes (Figure 1). Native DNA, with phosphodiester
internucleotide linkages, proved to be too unstable for work in cell culture or in vivo. Thus a
large number of chemical modifications were developed to enhance the biological
effectiveness of antisense molecules (Figure 2). A common modification is the substitution
of sulfur for oxygen in the phosphate backbone leading to phosphorothioate (PS)
oligonucleotides. These are considerably more stable than native DNA in the biological
milieu; however they have the potential disadvantage of being ‘sticky’ and binding non-
specifically to proteins. Another important set of modifications involves substitution of
aliphatic residues at the 2’ position of the nucleoside sugar thus creating 2’-O-Methyl and
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similar derivatives. This results in molecules that are more RNA-like and often bind with
higher affinity to RNA. Another important modification is represented by locked nucleic
acids (LNAs) where a 2’–4’ bridge results in oligonucleotides with very high binding
affinity. Finally, families of uncharged oligonucleotides have been created by radical
modification of the backbone. Replacement of the phosphodiester backbone with peptide
linkages gives rise to peptide nucleic acids (PNAs), while inclusion of non-ionic
phosphorodiamidate linkages gives rise to morpholino oligonucleotides. These backbone
modified molecules, as well as the 2’ modifications, do not recruit RNAse H but do retain
excellent base pairing specificity and the ability to influence other processes involving
mRNA such as message splicing and protein translation1,2.
siRNA and miRNA
A surge of recent discoveries have fundamentally altered our understanding of the role of
RNA in the cell. Not only is mRNA the key link between the genome and proteome, but
multiple other forms of RNA are now known to play critical roles in virtually all aspects of
gene expression3. From the therapeutic perspective siRNA and miRNA have evoked the
greatest interest. Short (~21 base pair) double stranded RNA segments can be loaded onto
the multi-protein RISC complex4. For siRNA action the Argonaute 2 (Ago 2) protein is the
critical element of the RISC complex; this protein degrades one of the two strands (sense
strand) while retaining the other (the antisense or guide strand). The loaded RISC complex
then surveys mRNAs in the cytosol and selects for perfect complementarity. The mRNA in
the RNA/RNA duplex is then cut at a position10 bases from the 5’ end of the guide strand,
and the two fragments of the mRNA are then further degraded by other enzymatic processes.
See Figure 1. The actions of miRNAs are also mediated by the RISC complex but in this
case there is usually not full complementarity between the guide strand and the target
mRNA and the binding sites are often in the 3’ untranslated region of the mesage5. See
Figure 1. This results in message sequestration into P-bodies6, interruption of translation,
and often in degradation. Since only partial complementarity is needed this means that a
single miRNA may interact with multiple mRNAs and thus be involved in the regulation of
multiple genes. While in some cases miRNAs themselves have be used to modify expression
of disease-related genes7, a more common approach is the use of ’antagomirs’, antisense
oligonucleotides complementary to the miRNA that can bind and inactivate it8.
Splice Switching Oligonucleotides
An important approach involves the use of so-called ‘splice switching antisense
oligonucleotides’ (SSOs). Although the human genome contains only about twenty thousand
genes it can direct the production of hundreds of thousands of proteins via alternative
splicing of pre-mRNA. Using oligonucleotides complementary to splice junctions it is
possible to re-direct the nuclear splicing machinery to include or exclude particular exons
(or segments of introns)9. See Figure 1. The SSO must be designed so that it does not recruit
RNaseH or the result would be degradation rather than altered splicing. Fortunately this is
easy to do using either oligonucleotides that are fully substituted at the 2’ position, or that
have uncharged backbones. The SSO technology will hopefully be useful in the many
human diseases that involve defects in splicing; additionally, through manipulation of the
splicing of reporter genes, it has provided a very convenient assay for measuring the
effectiveness of delivery of oligonucleotides to the nucleus10.
Off-Target Effects
In theory antisense, siRNA, and SSO oligonucleotides should be capable of modulating the
expression of only the target gene and no other gene. However, in practice there are several
sources of off-target effects of oligonucleotides. Simplest to understand are situations where
there is partial complementarity between the target message and another message. Another
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source of off-target effects relates particularly to phosphorothioate oligonucleotides that tend
to bind non-specifically to many proteins. In addition, any single-stranded oligonucleotide
can fold to form a three-dimensional structure that can act as an aptamer11 and thus serve as
a ligand for proteins. Finally, many types of oligonucleotides interact with Toll-Like
Receptors (TLRs) or other components of the innate immune system12 to trigger the
expression of cytokines and other genes involved in host defense mechanisms.
Pharmacokinetics and Biodistribution of Oligonucleotides
There is a vast literature on this topic including excellent recent reviews13,14; however the
essence can be described rather briefly. Systemically injected oligonucleotides rapidly
(minutes) leave the blood compartment and are redistributed to various tissues1516. Since the
molecular mass of most oligonucleotides is well below the cut-off for renal filtration, there
is a second phase of clearance (minutes-hours) when the oligonucleotides exit from tissues
stores and are excreted in the urine. An exception to this is the case of phosphorothioates,
since they tend to bind to plasma and tissue proteins thus substantially prolonging their
lifetime in the body14. While systemically administered oligonucleotides can enter most
tissues to some degree (other than the CNS), both antisense and siRNAs tend to be most
highly accumulated in tissues that are rich in reticuloendothelial cells including the liver and
spleen, or in kidney proximal tubule cells13,17. This natural biodistribution has influenced
the choice of therapeutic targets for oligonucleotide pharmacology.
Cellular Uptake and Subcellular Trafficking of Oligonucleotides
Being large, polar molecules oligonucleotides do not permeate across biological membranes.
In general oligonucleotides enter cells by some form of endocytosis and then traffic to
diverse subcellular compartments. Recently the complexity of oligonucleotide uptake and
intracellular trafficking and its role in determining the functional effectiveness of these
molecules has become better appreciated10,18–21. As depicted in Figure 3 there are multiple
mechanisms of endocytosis leading to distinct intracellular membrane-bound compartments
including early and late endosomes, lysosomes, the Golgi apparatus and the endoplasmic
reticulum22. Much of the oligonucleotide that accumulates in cells becomes non-
productively trapped in endomembrane compartments. However, because of the dynamic
nature of intracellular trafficking processes, a small amount of oligonucleotide can ‘leak’ to
the cytosol and diffuse into the nucleus23. It is this minor component of the total cellular
pool that is pharmacologically active. In general phosphorothioate-based antisense
molecules are taken up more effectively than either siRNA or uncharged single-strand
oligonucleotides; however even the phosphorothioates are subject to endosome trapping.
Clinical Evaluation of Oligonucleotides
There has been an enormous effort to mature oligonucleotide pharmacology to the point of
human application with numerous ongoing clinical trials of both antisense and siRNA13,24.
In most cases oligonucleotides in current studies in humans are given as ‘free’ molecules,
not associated with any sort of carrier or delivery system. However, a few trials involved use
of lipid-based delivery systems. The oligonucleotides being tested clinically mainly
incorporate relatively simple chemical modifications such as use of 2’-O-Methoxyethyl
residues in antisense or F or 2’-O-Methyl modifications of siRNA. Many of the intended
targets are cancer-related; however, there are also examples of trials that focus on local
administration such as inhalation25, or on targets in the liver26, an organ that tends to
accumulate oligonucleotides. A very exciting development is the testing of both
morpholino27 and 2’-O-Methyl28 SSOs to correct (at the RNA level) the genetic defect in
Duchenne muscular dystrophy, an otherwise incurable disease.
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Key Challenges for Oligonucleotide Pharmacology
Despite some promising clinical developments with ‘free’ antisense or siRNA molecules,
there remain concerns about the inability of these compounds to permeate membranes, their
unproductive accumulation in endosomes, and their poor pharmacokinetic and
biodistribution profiles16,29. Additionally, it would be highly desirable to be able to ‘target’
oligonucleotides to specific cells or tissues and thus enhance their selective therapeutic
actions. Much work has been devoted to addressing these challenges with the major thrusts
being the development of lipid based or polymer based nanocarrier systems as summarized
in recent reviews30,31. In this Account, however, we will focus solely on molecularly
defined chemical conjugates as an alternative strategy for overcoming the challenges of
oligonucleotide pharmacology.
2. Chemical Conjugation of Oligonucleotides
Much of the work on chemical modification of oligonucleotides has been directed at
increasing stability in the biological milieu, improving potency, and reducing off-target
effects1,2. More directly related to this Account is the chemistry underlying conjugation of
oligonucleotides with molecules designed to improve intracellular delivery or in vivo
pharmacokinetics and biodistribution32. An excellent recent review delineates many of the
issues involved in the conjugation of oligonucleotides with various partners33. For example,
the merits of solid phase versus solution phase conjugation are discussed. The former is
highly efficient and facilitates purification; however, it is limited by the availability of
appropriate synthons and by the need for both partners of the conjugate to be stable under
the conditions of synthesis. In contrast, solution phase conjugation allows synthesis of each
component under the most appropriate conditions, but the conjugation reaction may be
inefficient and substantial purification problems can occur. This review also discusses
specific aspects of the conjugation of oligonucleotides with peptides, carbohydrates and
lipophilic molecules. Another useful review focuses entirely on solid phase synthesis of
oligonucleotide conjugates34. Recent reports have brought new conjugation strategies to
bear; this includes use of “click chemistry”3536 and conjugation via phosphoramidation
reactions37.
Peptides
Perhaps the most extensive studies on peptide-oligonucleotide conjugation have been done
in the context of PNA and morpholino SSOs38,39. While it is possible to produce peptide/
PNA chimeras by solid phase synthesis, in most cases peptide-oligonucleotide conjugates
are formed by solution phase conjugation of the peptide to the oligonucleotide followed by
purification. A variety of linkages have been used including amide, thioether, thiol-
maleimide, ester, and disulfide. Conjugates of peptides with non-charged oligonucleotides
are purified by reversed phase HPLC while conjugates with charged oligonucleotides are
usually purified by ion exchange or by large scale PAGE. In our hands we have found that
analysis by MALDI-TOF mass spectrometry is suitable for many peptide-oligonucleotide
conjugates but that some of the larger conjugates require use of electrospray ionization mass
analysis. An important question is whether it is essential to use a bioreversible linkage such
as a disulfide in order to attain biological activity. This does not seem to be the case
however, and experience in our laboratory40,41 as well as by others42 has shown that both
bioreversible and non-reversible linkages can work well.
Lipids
The addition of lipophilic moieties to antisense and especially siRNA has proven to be a
powerful approach to modification of the pharmacokinetic and pharmacodynamic
characteristics of oligonucleotides. In particular conjugation with cholesterol promotes the
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interaction of the oligonucleotide with albumin and serum lipoproteins and subsequently
promotes tissue uptake primarily via the hepatic lipoprotein receptors43. Tocopherol
(Vitamin E) conjugates have also been used in a similar context44. In general simple
lipophilic groups can be incorporated via solid phase synthesis using the appropriate
phosphoramidites, some of which are commercially available. Chemical aspects of lipid
conjugation to oligonucleotides as well as the physical properties of such conjugates have
been extensively discussed in a recent review45.
Carbohydrates
Conjugation of oligonucleotides with carbohydrate moieties can provide a powerful
approach to targeting the lectin-like proteins that exist on many cell types. While linking a
monosaccharide to an oligonucleotide is relatively simple and can be approached through
the preparation of carbohydrate containing phosphoramidites, synthesis of oligonucleotides
bearing the more complex oligosaccharide structures needed for optimal lectin recognition is
far more challenging34. Recently ‘click’ chemistry has been applied to the preparation of
several types of oligonucleotide glycoconjugates including rather complicated branched
oligosaccharides46,47.
Nucleic Acids
The formation of conjugates or chimeras of antisense or siRNA oligonucleotide with other
nucleic acids moieties has some very interesting ramifications. One approach has been to
prepare chimeras of siRNA with aptamers that target specific cell surface receptors.
Typically a polynucleotide comprising the ‘passenger’ (sense) strand of the siRNA linked to
the aptamer is synthesized by in vitro transcription, including the incorporation of 2’-F
pyrimidines; thereafter the ‘guide’ (antisense) stand is complexed by hybridization48,49.
3. Receptor Targeted Conjugates
Lately there has been a substantial increase in work on receptor targeting of oligonucleotides
via conjugation5019. For example, our laboratory has described Arg-Gly-Asp (RGD) peptide
conjugates of splice switching antisense oligonucleotides (SSOs) that can be effectively
delivered to melanoma cells in culture via the αvβ3 integrin40. The RGD-SSO conjugates
have also been tested to a limited degree in xenograft models of melanoma and have shown
some activity (Figure 4). We have also studied conjugates of SSOs to bombesin, a peptide
that binds with high affinity to BB2, a G Protein-Coupled Receptor that is over-expressed in
some tumors including prostate cancer10 and have demonstrated substantial receptor-
dependent effects in this system. We have also used anisamide, a high affinity small
molecule ligand for the sigma receptor, to target oligonucleotides selectively to tumor cells.
The anisamide–SSO conjugates were prepared by a novel solid phase method that involves
creation of phosphoramidites of the ligand51. We have recently extended the RGD targeting
approach to siRNA. Thus bi-, tri-, and tetra-valent RGD conjugates of a potent luciferase
siRNA were synthesized52. As compared to un-conjugated siRNA, each of the RGD-
conjugates displayed a remarkably increased and highly receptor-selective uptake into M21
melanoma cells that express the αvβ3 integrin. Interestingly however, only the tri- and tetra-
valent conjugates displayed significant ‘knockdown’ effects. The issue of valency is a
complex one in the context of conjugates between oligonucleotides and high affinity ligands.
Initially we had assumed that increasing valency would lead to increased avidity and thus
increased cell uptake and biological effect. However, in our experience this simple pattern
does not necessarily prevail. For example, increasing valency does not necessarily lead to
increased cell uptake. We have found this both with RGD-siRNA conjugates52 and with
bombesin-SSO conjugates (unpublished). However, in the case of the RGD-siRNA
conjugates there was an increased biological effect of the higher valency conjugates even
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though uptake levels were similar. We hypothesize that this behavior may be based on
different intracellular trafficking of the various conjugates. Recently evidence has been
accumulating that the route of intracellular trafficking can profoundly influence the
pharmacological activity of oligonucleotides18,21.
As mentioned above, there has been considerable recent interest in using nucleic acid
conjugates or chimeras for the targeting of siRNA. One example involves the delivery of
siRNA by targeting TLRs53. An un-methylated CpG DNA oligonucleotide known to bind to
TLR9 was chemically conjugated to a siRNA. This resulted in enhanced ‘knockdown’ of
endogenous and reporter genes in immune system cells known to express TLR9. In in vivo
studies, a CpG siRNA targeting the immunosuppressive regulator Stat3 resulted in enhanced
antitumor immune responses. A very promising approach to selective delivery of
oligonucleotides involves use of nucleic acid aptamers11. A pioneering report described the
biological effects of chimeric molecules comprised of an aptamer with high affinity for the
Prostate Specific Membrane Antigen (PMSA) surface glycoprotein linked to siRNAs that
affected key survival genes including Plk1 and Bcl254. In cell culture, the aptamer-siRNA
chimeras were taken up efficiently by cells that expressed PSMA and they effectively
reduced the target mRNAs. When administered by direct intra-tumoral injection the
chimeras produced a significant tumor growth inhibition. A chemically optimized version of
a PSMA aptamer-Plk1siRNA chimera displayed antitumor activity against PMSA-
expressing tumors when given by systemic administration48. Other important examples of
aptamer-siRNA chimeras are also beginning to emerge. Thus an aptamer siRNA chimera
that bound to the viral gp120 protein was able to substantially reduce viral loads in HIV
infected humanized mice49. Similarly an aptamer targeting the T-cell CD4 receptor linked to
antiviral siRNAs was able to protect against vaginal HIV transmission in humanized mice55.
In another study, PSMA-siRNA chimeras inhibited tumor growth in vivo using siRNAs
directed against Upf2 and Smg1, two genes involved in nonsense mediate mRNA decay and
thus in immune regulation of tumors56.
The various studies discussed above, using receptor-targeted conjugates of antisense or
siRNA strongly suggest that monomeric ligand-oligonucleotide conjugates can produce
significant biological effects both in cell culture and in vivo without the use of any
transfection agents. In many cases strong pharmacological effects can be attained at
nanomolar levels of targeted SSO or siRNA. Despite these promising early studies there are
several issues that must be addressed to allow further progress. A major impediment is the
dearth of knowledge about the uptake and trafficking mechanisms involved in receptor
mediated oligonucleotide delivery. Additionally many synthetic challenges remain. While it
is relatively easy to make monovalent peptide-oligonucleotide conjugates, more complex
conjugations are much more demanding. Thus, conjugates incorporating large nucleic acid
aptamers, or multi-valent peptide ligands, can be challenging to synthesize and hard to
purify.
4. Conjugates with Cell Penetrating Peptides
Cell Penetrating Peptides (CPPs) are peptides, usually cationic, that purportedly possess the
ability to cross membranes and also to convey attached ‘cargos’ such as other peptides,
proteins, or nucleic acids across the membrane as well. The TAT and Antennepedia peptides
are early examples of CPPs, but a large variety of new CPPs have been described more
recently57,58. Initially it was believed CPPs or CPP-cargo conjugates could directly
translocate across the plasma membrane. However, this view has been radically revised and
most studies suggest that cationic CPPs initially bind to negatively charged proteoglycans at
the cell surface, are subsequently internalized into endosomes, and may then escape from
endosomes to enter the cytosol. An important consideration is that the nature of the attached
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cargo plays a major role in CPP uptake mechanisms and in the effectiveness of cytosolic
delivery; as might be anticipated, smaller cargos are more effectively delivered to the
cytosol while larger moieties are primarily retained within endosomes59,60.
Although there have been numerous studies of both chemical conjugates and noncovalent
complexes of antisense and siRNA with CPPs, the utilization of CPPs for intracellular
delivery of oligonucleotides has had a somewhat checkered history38,50. In general, the
conjugation of CPPs with charged oligonucleotides has not led to effective compounds. One
issue is the tendency of the positively charged CPPs and the anionic oligonucleotides to
aggregate and form insoluble complexes. However, conjugation with uncharged
oligonucleotides such as morpholinos or PNAs has been more promising. Thus studies with
conjugates of novel CPPs to PNA61 or morpholino62 SSOs have shown excellent splice-
correction activity in cell culture, and promising therapeutic performance in mouse models
of Duchenne muscular dystrophy63,64. An interesting approach involves synthesizing CPP-
oligonucleotide conjugates that also contain a lipid moiety65; this seems to lead to enhanced
endosomal escape and thus greater efficacy of the conjugated PNA SSO. A parallel
approach has been to create nanoparticle complexes of anionic oligonucleotides and cationic
CPPs; this strategy has been recently reviewed in detail66, but is really outside of the scope
of the current article and will not be further discussed. A potential limitation with CPP-SSO
conjugates is that, as with unconjugated SSOs, they usually require micromolar
concentrations (or the in vivo equivalent) to attain significant biological effects. This may
indicate that CPPs are only partially effective in releasing endosomal stores of
oligonucleotides. As mentioned previously, SSOs are being evaluated clinically27,28;
hopefully the further development of novel, non-toxic CPP-SSO conjugates may provide
enhanced therapeutic effects.
5. Conclusions
While chemical modification has been an important part of the entire history of
oligonucleotide research, the sub-topic of oligonucleotide conjugation has become
particularly active recently. New strategies such as ‘click chemistry’ and various solid-state
approaches have made conjugation with complex partners more accessible. The field is
developing experience with the conjugation of a variety of moieties including peptides,
lipids, carbohydrates and other forms of nucleic acids, and the biological ramifications of
various types of conjugates are becoming better understood. A somewhat surprising
generalization is that the linker between oligonucleotide and its partner moiety can be quite
varied with relatively little impact on the biological potency of the conjugate (although
exceptions will no doubt occur). Coupling to ligands that bind selectively to cellular
receptors seems a very promising approach for both single stranded oligonucleotides and
siRNA. Impressive successes in cell culture and in vivo have been attained with nucleic acid
aptamers as ligands, while peptide-oligonucleotide conjugates also have demonstrated
potency and specificity. Reports on the biological properties of lipid and carbohydrate
conjugates have not been as abundant in the published literature, but there is certainly a
good deal of activity concerning these approaches. Cell penetrating peptides have found an
important niche in the delivery of uncharged oligonucleotides, primarily of the SSO type
that have such great potential in the treatment of genetic diseases. Further developments in
the chemistry of CPPs should augment their potential as delivery agents. As interesting
concept is whether some of the beneficial properties of receptor-targeted ligands and of
CPPs could be combined in the same oligonucleotide conjugate thus improving both cellular
specificity and intracellular delivery.
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Figure 1. Oligonucleotide Mechanisms of Action
Four mechanisms are illustrated. In the nucleus: (i) classical antisense (ASO) mediated
mRNA degradation via ribonuclease H; (ii) alteration of exon choice using splice switching
oligonucleotides (SSO). In the cytosol: (iii) siRNA mediated mRNA degradation via the
Ago 2/RISC complex; (iv) miRNA modulation of mRNA function.
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Figure 2. Common Chemical Modifications of Oligonucleotides
Other than the morpholino and PNA backbone modifications that form uncharged
molecules, the various chemistries shown can be applied to siRNA as well as to single
stranded oligonucleotides.
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Figure 3. Pathways of Endocytosis and Intracellular Trafficking
Several of the illustrated endocytotic pathways have been associated with the uptake of
various types of oligonucleotide conjugates or of ‘free’ oligonucleotides. Various
intracellular membranous organelles are also illustrated as are some of the proteins
associated with trafficking pathways. The Rab proteins are GTPases that help to guide
intracellular traffic. (reproduced with permission23).
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Figure 4. In Vivo Effects of a Targeted Oligonucleotide Conjugate
A RGD-SSO conjugate was used in these experiments. Human A375 melanoma cells were
stably transfected with a luciferase reporter cassette that responds to an appropriate SSO by
increasing production of properly spliced luciferase message and functional luciferase
protein. The cells were then used as xenografts in SCID mice. After the tumors were
established the animals were treated with 10 mg/kg of RGD-SSO or unconjugated SSO or
with saline. Three days later luciferin was injected and photon emission due to luciferase
was measured on an optical imaging system. Induction of luciferase was approximately 3-
fold stronger in the animals treated with RGS-SSO as compared to free SSO while treatment
with saline had no effect.
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